Clinical Trial Update: Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of AMG 232 (KRT-232) in patients with brain cancers including glioblastoma and gliosarcoma was terminated; the study evaluated the drug…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma
• Mgmt-unmethylated Glioblastoma

Drugs mentioned

• AMG 232 (KRT-232)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioblastoma, Gliosarcoma | Phase 1 | Status: TERMINATED